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Abstract 
 
Aptamers are single-stranded nucleic acids that selectively bind to target molecules. Most aptamers are 
obtained through a combinatorial biology technique called SELEX. Since aptamers can be isolated to 
bind to almost any molecule of choice, can be readily modified at arbitrary positions and they possess 
predictable secondary structures, this platform technology shows great promise in biosensor 
development. Over the past two decades, more than one thousand papers have been published on 
aptamer-based biosensors. Given this progress, the application of aptamer technology in biomedical 
diagnosis is still in a quite preliminary stage. Most previous work involves only a few model aptamers 
to demonstrate the sensing concept with limited biomedical impact. This Critical Review aims to 
summarize progresses that might enable practical applications of aptamer for biological samples. First, 
general sensing strategies based on the unique properties of aptamers are summarized. Each strategy 
can be coupled to various signaling methods. Among these, a few detection methods including 
fluorescence lifetime, flow cytometry, upconverting nanoparticles, nanoflare technology, magnetic 
resonance imaging, electronic aptamer-based sensors, and lateral flow devices have been discussed in 
more detail since they are more likely to work in a complex sample matrix. The current limitations of 
this field include the lack of high quality aptamers for clinically important targets. In addition, the 
aptamer technology has to be extensively tested in a clinical sample matrix to establish reliability and 
accuracy. Future directions are also speculated to overcome these challenges.  
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1. Introduction 
Biomedical diagnosis is a central component of the modern healthcare system, allowing (early) 
detection of diseases and monitoring therapeutic progresses.1-6 Since a disease state is often associated 
with the deviation of certain molecular signatures from normal conditions, accurate and selective 
measurement of the structural and concentration change of disease marker molecules is a major goal of 
the current analytical chemistry. Disease markers can be found at a few different levels, including DNA, 
RNA, proteins and small molecule metabolites.7-9 Both analytical instruments and biosensors have been 
used in biomedical diagnosis. Instrumentation methods such as mass spectrometry and NMR can 
provide rich information not only about analyte concentration but also structure. In addition, multiple 
target molecules might be measured at the same time. However, sample pre-treatment is often required 
and a long turnaround time (often days) is needed to obtain the result since such assays cannot be 
performed on-site. Desirable diagnosis should provide immediate results on site during a patient visit or 
at home with a minimal sample volume and non-invasively. In this regard, biosensors have many 
operational advantages such as fast detection, ease-of-use, portability, cost-effectiveness and ease of 
mass production, which make them ideal choices to meet the growing needs for biomedical 
diagnostics.10-12  
A biosensor contains two main components: a biological recognition element that detects the 
target molecule and a signaling component that converts the biological recognition into physically 
detectable signals. Recognition molecules are crucial for biosensors since their binding affinity and 
specificity determines the sensor performance. So far, a diverse range of recognition molecules have 
been employed. Antibodies have been the most commonly used probes since they can selectively bind a 
broad range of analytes with high affinity. The commercial availability of antibodies is another strong 
support for their research and development. However, antibodies also exhibit certain limitations. For 
instance, antibodies are sensitive to temperature and prone to irreversible denaturation.13 The 
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production of antibodies often involves animals suffering batch-to-batch variation. In addition, 
antibodies have high molecular weight and it is difficult to achieve site-specific labeling. Finally, 
antibody-based assays often require immobilization and extensive washing, while it is difficult to carry 
out homogeneous assays. Therefore, it is highly desirable to seek alternative ligands as a new platform 
for biomedical diagnosis.  
Since the early 1990s, aptamers have attracted tremendous attention.14,15 Aptamers refer to single-
stranded nucleic acids that can fold into specific 3D structures and selectively bind to target molecules. 
Most aptamers are obtained through a combinatorial selection process called systematic evolution of 
ligands by exponential enrichment (SELEX). SELEX has resulted in many aptamers that can bind to a 
broad range of targets, including metal ions, small molecules, peptides, proteins, and even complex-
target such as the whole cell and materials surfaces. Aptamers are attractive for biosensor development 
due to their small size, high stability (especially DNA aptamers), high binding affinity and specificity, 
and ease of modification.16,17 First, aptamers can in principle be selected for any given target, including 
those without soliciting immune responses or with high toxicity. Second, chemical synthesis of 
aptamers is well developed, leading to highly reproducible reagents that can be labeled at arbitrary 
positions with a variety of functional groups. Third, DNA aptamers are more stable than proteins and 
can be repeatedly used without losing their binding capability. Fourth, aptamers have little 
immunogenicity or toxicity. Finally, due to their small size, aptamers may achieve a higher density for 
immobilization and bind to epitopes that are not easily accessed by antibodies. 
With these advantages, significant advances have been made on aptamer-based sensing. By a 
search of the ISI Web of Knowledge database, more than 1200 papers have been published as of 
November 2013 under the keywords of ‘aptamer’ and ‘biosensor’; the number of papers has been 
growing exponentially (Figure 1A). This is also a global effort (Figure 1B). While a number of 
aptamer-based drugs and targeting molecules have entered clinical trials (see Table 1) and have even 
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been approved, such as Macugen, few aptamer-based diagnostic products are on the market. Given the 
amount of knowledge accumulated in the past two decade, this is a good time to critically summarize 
this field and identify new solutions to move forward. Numerous review papers have already been 
published on various aspects of the aptamer biosensor field at different stages of development,4,16,18-28 
and we do not intend to provide a comprehensive review here. In this Critical Review, we first briefly 
describe aptamer selection and general biosensor design strategies, keeping in mind biomedical 
diagnosis as the application goal. Following that, specific designs that are promising for clinical 
applications are discussed.  
 
Figure 1. (A) The number of publications under the keywords of ‘aptamer’ and ‘biosensor’ from 1998 
to November 2013. (B) The distribution of the publications from different countries.  
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Table 1. Aptamers in Clinical Development. ( Source from http://www.clinicaltrials.gov and reference 29,30) 
Aptamer Condition Target Phase Identifier 
ARC1905 
Age-related macular 
degeneration 
Factor C5 of the 
complement cascade 
Phase I 
NCT00950638 
NCT00709527 
E10030 
Age-related macular 
degeneration 
Platelet-derived growth 
factor-B (PDGF-B) 
Phase I 
Phase 
III 
NCT01089517 
NCT00569140 
NCT01944839 
NCT01940900 
EYE001 
Macular Degeneration 
Choroidal Hippel-Lindau 
Disease 
Vascular endothelial 
growth factor(VEGF) 
Phase 
II/III 
Phase I 
NCT00021736 
NCT00056199 
REG1 
(RB006/ RB007) 
Coronary Artery Disease 
Acute Coronary Syndrome 
Healthy 
Factor IXa 
Phase II 
Phase II 
Phase I 
NCT00715455 
NCT00932100 
NCT00113997 
EYE001 Hippel-Lindau Disease 
Vascular endothelial 
growth factor(VEGF) 
Phase I NCT00056199 
AS1411 Acute Myeloid Leukemia Nucleolin Phase II NCT01034410 
NOX-E36 
Chronic Inflammatory 
Diseases 
Monocyte chemotactic 
protein-1 (MCP-1) 
Phase I NCT00976729 
NOX-A12 
Autologous stem cell 
Transplantation 
Hematopoietic Stem Cell 
Transplantation 
Stromal cell-derived 
factor-1 (SDF-1) 
Phase I 
NCT00976378 
NCT01194934 
ARC1779 Von Willebrand Disease 
A1 domain of von 
Willebrand Factor (vWF), 
Phase II 
NCT00632242 
NCT00694785 
BAX499 
(ARC19499) 
Hemophilia 
tissue factor pathway 
inhibitor(TFPI) 
Phase I NCT01191372 
NU172 Heart Disease Thrombin Phase II NCT00808964 
 
 
2. Aptamer Selection. 
Since its inception in 1990, the majority of aptamers have been isolated using SELEX.31-35 In 2002, 
the first naturally occurring aptamers known as riboswitches were found in the untranslated regions of 
many bacterial mRNA.36 Since riboswitches are made of RNA and are often quite large, they have not 
been widely used for sensing outside cells and will not be reviewed here. A typical SELEX scheme is 
presented in Figure 2, where a large random DNA or RNA library (1013-1015) is subjected to an 
iterative process of in vitro selection and amplification. After mixing the library with the target 
molecule, a critical step is the separation of binding aptamers. Depending on the property of each target 
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molecule, the separation strategy can be quite different. Small molecule targets are often covalently 
immobilized on a column and non-bound DNA can be washed away. Protein targets often involve a 
filter membrane to pass the unbound free DNA while retain the DNA/protein complex. For even larger 
targets such as cells, separation is achieved by centrifugation. The isolated binding DNA is amplified 
by PCR to seed the next round of selection. Numerous modifications have been made to improve the 
critical step: separation of binding aptamers from the unbound DNA, such as using capillary 
electrophoresis,37-40 microfluidic devices,41-45 AFM tips,46 and magnetic beads.47  
Given that hundreds of aptamers have already been isolated, there are still a number of issues to be 
addressed at the SELEX step. For small molecule targets, selections were often carried out by 
covalently attaching the target to a solid support. The resulting aptamers give low M Kd, while many 
riboswitches can bind targets at low nM affinity. One striking example is for guanine binding. 
Compared to the natural riboswitch with a Kd of 5 nM,
48 a selected RNA aptamer exhibits a Kd of 1.3 
M.49 This difference can be attributed to the inaccessibility of part of the target molecule during 
selection due to covalent immobilization and the larger size of the riboswitch allowing more complex 
binding structures. Membrane proteins interesting for biomedical diagnosis are often selected with 
purified outer membrane fragments. However, natural proteins might be quite different in folding with 
different glycosylation patterns. Furthermore, most selections are carried out in buffers different from 
the actual detection conditions. The change of pH, ionic strength, temperature and the presence of 
matrix molecules can all adversely affect target binding. To address some of these problems, new 
selection strategies especially cell-SELEX50,51 and tissue-SELEX52 have been developed, providing 
new promising analytical reagents.  
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Figure 2. Isolation of aptamers using SELEX. In this example, the target molecule is immobilized on a 
bead to achieve separation. 
 
3. Biosensor design strategies. 
Once an aptamer sequence is known, an assay can be designed to measure its target molecule. 
Aptamers can be used in a similar way to antibodies for simple binding. But beyond that, many other 
assays unique to aptamers have been demonstrated. Most of them take advantage of the programmable 
property of nucleic acids. For example, a conformational change into a well-defined binding structure 
is often associated with aptamer binding.53 Until now, more than one thousand papers have been 
published on this topic. Since many comprehensive reviews are available for aptamer-based 
sensors,18,19,54-59 we only outline a few general design strategies. Each method can be coupled with 
various signaling methods.  
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3.1. Simple binding based assays. Since aptamers are affinity ligands, they may replace antibodies in 
ELISA (enzyme-linked immunosorbent assay).60-62 Target binding to immobilized aptamers may also 
increase the mass or refractive index nearby the surface (Figure 3A).63-65 However, simple binding 
based assays require extensive washing. This is particularly important for biomedical samples since 
they often contain a high concentration of serum proteins. Another form of antibody-based assay is 
immunoprecipitation.66 Since each antibody has multiple Fab arms and a target protein often has a few 
epitopes, the system can crosslink to precipitate. By attaching multiple aptamers to a nanoparticle, 
similar precipitants can also form with protein targets.67-70 If AuNPs are used, the color might change to 
blue or purple due to coupling of the gold surface plasmon band (Figure 3E).  
 
Figure 3. Various aptamer-based biosensor design strategies. (A) Simple binding-based assays. ELISA, 
mass or refractive index change induced by target binding can be tested on this platform. (B) FRET-
based assays using binding induced aptamer conformational change. (C) Structure-switching aptamer 
design. (D) Self-assembly of split aptamer in the presence of target molecules. (E) Detection based on 
target-induced AuNP aggregates. (F) Using graphene oxide (GO) adsorbed probe DNA for detection. 
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(G) Nanoparticle assembly induced by target binding of split aptamers. (H) Design of fused aptamer 
sensors using the MG for signaling. 
 
3.2. Aptamer folding based sensors. While antibody binding does not change its global 
conformational, aptamers do. Such conformational changes may be used to avoid artifacts due to non-
specific binding.26 For example, aptamer conformational change may alter the local environment of an 
attached fluorophore. Based on this assumption, Ellington and co-workers test single fluorophore 
labeled aptamers.71 However, it is not straightforward to choose the most efficient labeling site and the 
amount of signal change is often quite modest. The performance of sensing is significantly improved 
by introducing an external quencher. In most designs, the two ends of an aptamer are labeled with a 
fluorophore and a quencher, respectively (Figure 3B). The fluorophore emission is thus sensitive to the 
end-to-end distance change. Such methods have been used to detect K+,72 cocaine,73 adenosine/ATP,74 
and proteins.75 In addition to using fluorophores, aptamer folding can also be detected using AuNPs. 
For example, folded aptamers cannot be easily adsorbed by AuNPs, while unfolded ones can be 
adsorbed to give better colloidal stability of AuNPs.76,77 
3.3. Structure-switching signaling aptamers. Since an aptamer is also a piece of DNA, it can bind to 
its complementary DNA (cDNA). Therefore, an aptamer can be designed to switch between two 
distinct binding structures. One example is shown in Figure 3C, where a quencher-labeled cDNA is 
hybridized to a fluorophore-labeled aptamer. Initially the fluorescence is quenched. In the presence of 
the target, the quencher containing strand is released, leading to signal increase.78 Compared to the 
small end-to-end distance change within the aptamer, this method generates a much larger distance 
change and fluorescence enhancement.79-85 The fluorophore/quencher can be replaced by other 
signaling moieties such as electrode surfaces,86,87 quantum dots,88 or metal nanoparticles89 for other 
types of signal transduction. In addition to using cDNA to lock the initial aptamer conformation, a 
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variation is to use an inorganic surface to adsorb the DNA probe. One of the most cited examples is 
graphene oxide (GO), which efficiently adsorbs ss-DNA and also serves as a fluorescence quencher. In 
the presence of the aptamer target, the adsorbed DNA can desorb to show fluorescence enhancement 
(Figure 3F).90  
With an external quencher and a large change in distance upon target binding (e.g. from zero to 
infinite), the amount of signal increase is quite large. The downside of the structure-switching design, 
however, is the decreased aptamer binding affinity due to competition from the cDNA or inorganic 
surface.78 In addition, when the sensor system contains two pieces (Figure 3C), it is difficult to achieve 
continuous target monitoring since the released probe is unlikely to re-hybridize in a short time. Overall, 
this is a widely used signaling method unique for aptamer and it is next to impossible to have such 
rational structural changes incorporated into an antibody.  
3.4. Split aptamer sensors. It is also possible to split an aptamer into two pieces. In the presence of 
target molecules, the two fragments can self-assemble to and change fluorescent signal.91,92 Yamamoto 
et al detected the HIV-1 Tat protein using this method.91 The aptamer sequence was divided into two 
pieces, with one piece in a hairpin structure containing a fluorophore and a quencher at the two ends. 
Without the target, the initial fluorescence was quenched. In the presence of Tat protein, the labeled 
fragment self-assembled with the other half to form a ternary complex, enhancing fluorescence due to 
separation of the fluorophore and quencher. Stojanovic et al also divided the anti-cocaine and anti-
adenosine aptamers into two halves, where successful sensing was achieved (Figure 3D).92 Pyrene 
excimer formation has also been used in this design.93 A variation of this is to immobilize each 
fragment on a AuNP to produce analyte-induced assembly (Figure 2F).94 In addition, split aptamers 
have been attached on fluid liposome surfaces.95 To engineer effective split aptamer sensors, the choice 
of splitting site is crucial. It is sometimes not straightforward to split an aptamer while still retaining its 
binding activity.96 In addition, the binding affinity decreases significantly since the originally dual-
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molecule reaction becomes a trimolecular reaction. 
3.5. Fused aptamers. Opposite to the split aptamers, two aptamer modules can be rationally fused for 
sensing. One module is for target recognition and the other for signal generation. For example, 
Stojanovic and Kolpashchikov appended the malachite green (MG) aptamer to three different aptamers 
(ATP, FMN and theophylline).97 MG is non-fluorescent by itself, but it becomes highly fluorescent 
upon binding to its RNA aptamer.98 In each case, MG binding was initially disfavored due to the lack of 
stable structures in the other aptamer (Figure 2H). With the target analyte, the MG binding pocket is 
formed to produce fluorescence. This type of label-free signaling method might be useful for direct 
imaging and detection inside cells.99 Similar methods have been applied for detecting proteins and 
other analytes.100,101 Other ways of linking two aptamers for sensing have also been reported.102,103  
In this section, we mainly used fluorescent assays to illustrate general sensor design strategies for 
aptamers. These strategies can be mounted on various signaling methods. Beyond fluorescence, 
colorimetric, electrochemical, Raman and magnetic resonance imaging have all been demonstrated. In 
the following section, we focus on a few specific methods that might be practically useful in 
biomedical diagnosis. 
 
4 Aptamer-based biosensors for biomedical diagnostics 
4.1. Practical considerations. It is quite interesting to note that while hundreds of aptamers have been 
selected and over one thousand sensing related papers have been published, only a handful of targets 
were used. In addition, few of these targets are of great clinical interest. This trend reflects a few 
difficulties faced by the field. The first challenge is the lack of high quality DNA aptamers for many 
clinically (and commercially) important targets, such as glucose, cholesterol and many other disease 
markers. A large number of the aptamer selections were carried out in companies and the detailed 
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sequence information is not published. In addition, useful aptamers should be of sufficiently high 
quality, detecting target analytes at their physiologically related concentrations. The lack of high quality 
and high impact aptamers has confined the impact of this field mostly to academic research. Second, 
many reported aptamers lack detailed characterization, making it difficult for analytical chemists to do 
further developments. For rational biosensor design, the secondary structure of aptamers should be 
known. This is probably a major reason for the repeated use of the same model aptamers. The third 
difficulty comes from the accessibility of target molecules, especially proteins and specific cell lines. 
This has disallowed a broader community to study those aptamers, while the labs with these reagents 
may not be interested in analytical development. This calls for more collaborative work. Fourth, the 
sensors and assays have to work in complex sample matrix. Fortunately, it has been demonstrated on 
many occasions that aptamers still selectively recognize their targets and are relatively immune to 
nonspecific interactions in serum.104-106 This is not surprising since natural riboswitches work well in 
the cellular environment. Many of the sensors are demonstrated in simple buffers, while blood, serum, 
urine and saliva are the most common biomedical samples; they are complex with strong optical 
interference. For example, blood samples are highly viscous with a deep red color. Most visible light is 
scattered or absorbed, resulting in a very high background for optical detection. In addition, direct 
binding assays often suffer from non-specific binding due to other proteins in the sample. Fifth, the 
sampling methods also need to be considered. Blood samples need to be obtained with minimal 
invasiveness and the sensor has to work with a small sample volume. Finally, there is always a barrier 
and competition from the established assays such as those based on antibodies. To be widely accepted 
by industry, aptamer-based assays need to be extensively tested to establish their accuracy, 
reproducibility and user friendliness, avoiding multiple steps of liquid sample transfer and mixing. The 
cost needs to be lower than competing technologies. To date, a lot of efforts have been made to address 
these problems. We herein review examples that might be eventually useful for biomedical diagnosis. 
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4.2 Time-resolved fluorescence. When monitoring proteins and metabolites in biological fluids, the 
background signal sometimes comes from the sample matrix. Instead of monitoring steady-state 
fluorescence intensity, one approach to decrease background interference is to use time-resolved 
fluorescence. Time-resolved fluorescence assays are based on the difference between the fluorescence 
lifetime of the detection signal and the nonspecific background (e.g. scattered and reflected excitation 
light or auto-fluorescence from the sample matrix). Usually the lifetime of background fluorescence is 
a few ns, which can be filtered using long lifetime probes such as pyrene. For example, Yang et al 
developed a wavelength-shifting dual-pyrene-labeled aptamer probe for detecting PDGF in biological 
fluids using both steady-state and time-resolved fluorescence.75 The aptamer was labeled with one 
pyrene at each end, and the two pyrenes are spatially separated without PDGF, resulting only in 
monomer emission at ~400 nm. The aptamer switches its emission to 485 nm (pyrene excimer) upon 
PDGF binding since the two pyrenes are then right next to each other. Importantly, the pyrene excimer 
has a much longer fluorescence lifetime (40 ns) than that of the background (5 ns). This time-resolved 
detection allows for the elimination of most of the background fluorescence.  
Zhang and co-workers argued that the fluorescence lifetime of the pyrene excimer is still too short 
to completely eliminate background signal. They introduced europium ions (Eu3+) as the fluorophore 
since lanthanides have a much longer lifetime that can reach ~1 ms.107 To detect adenosine deaminase 
(ADA), a biotinylated adenosine aptamer is first immobilized on a streptavidin-coated plate surface in 
the presence of adenosine. Without ADA, adenosine is associated with the aptamer, inhibiting binding 
of the cDNA with the Eu3+ label. With ADA, adenosine is converted to inosine that is not recognized by 
the aptamer. As a result, the cDNA is hybridized and Eu3+ is immobilized, allowing an enhanced 
lifetime signal to be detected. A detection limit of 2 U L-1 ADA was achieved, which can meet the 
clinical requirement of (4 U L-1). Importantly, this approach can be used to detect ADA in human serum 
quantitatively. Huang and co-workers reported another example of lifetime based assay for adenosine 
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detection based on home-made Eu3+ complexes (ENT).108 In these examples, the probes were also 
immobilized for detection. While high sensitivity can be achieved, it required a lot of washing steps. 
Recently, Lu and co-workers also reported a Tb3+ complex for homogeneous time-gated fluorescence 
detection. The Tb3+ complex has a lifetime on the order of ms. Using a delay time of 50 s, most 
interfering fluorescence was eliminated.109 This method detects adenosine in undiluted blood serum 
down to 60 M, comparable with that achieved in clean buffers. While the physical principle of such 
detection methods is attractive, measurement of fluorescence lifetime requires more sophisticated 
hardware and than measuring steady-state fluorescence intensity, making on-site detection more 
challenging. In addition, many of the published examples involve heterogeneous reactions. Developing 
homogenous assays is likely to be an important future direction.28  
4.3 Upconverting nanoparticles. Upconverting nanoparticles (UCNPs) convert a long wavelength 
excitation (often in the IR range) into shorter wavelength fluorescence (anti-Stokes emission). In this 
process, more than one photon needs to be absorbed before emission takes place. This anti-Stokes 
fluorescent property might be useful for bioassays conducted in complex matrices.110 First, IR light 
causes minimal photo damage to biological substances and less photobleaching. Second, IR light does 
not excite biological fluorophores that may be present in the sample matrix. Third, anti-Stokes 
fluorescence effectively reduces auto-fluorescence and light scattering, producing clean emission 
spectra with high signal-to-noise ratio. Finally, the synthesis of UCNPs is now mature and high quality 
particles can be routinely produced. It needs to be noted that the surface of UCNPs is often capped by 
hydrophobic ligands. These capping ligands are important not only for maintaining colloidal stability, 
but also for protecting the long lifetime luminescence of these particles. Since biosensing takes place in 
aqueous environments, various methods have been established for bioconjugation.111 Methods have 
also been developed to attach DNA to UCNPs.112,113 By now, UCNPs have been successfully applied to 
the detection of biomolecules such as proteins,114 DNA,115 and metal ions.116 
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Figure 4. Sensing with UCNPs. (A) Thrombin sensor based on FRET from aptamer-modified UCNPs 
to CNPs. (B) Sandwich assay with aptamer-functionalized AuNPs and UCNPs for PDGF detection.  
 
By using aptamer-functionalized NaYF4:Yb/Er UCNPs as the energy donor and carbon 
nanoparticles (CNP) as the energy acceptor, Wang et al developed a FRET-based biosensor for 
thrombin (Figure 4A).117 The absorption spectrum of CNP overlaps well with the emission spectrum of 
the UCNPs. Without thrombin, the aptamer-UCNP conjugate was brought in close proximity to the 
CNPs through π−π stacking and hydrophobic interactions between DNA and CNP, leading to quenched 
emission. In the presence of thrombin, the aptamer formed a G-quadruplex structure, decreasing the 
interaction with CNPs and restoring fluorescence. The sensor has a dynamic range from 0.5 to 20 nM 
with a detection limit of 0.18 nM thrombin. Importantly, the same linear range was obtained in human 
serum, indicating high robustness of the sensor. 
Lin et al developed a biosensor for PDGF-BB in blood serum based on FRET from UCNPs to 
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AuNPs (Figure 4B).118 In this system, the same aptamer was modified with either a thiol group to 
attach to AuNPs (Apt1-AuNPs) or an amine group to attach to UCNPs (Apt2-UCNPs). Since each 
PDGF-BB can bind to two aptamers, it is possible to form a sandwich structure with these two NPs, 
leading to FRET-based quenching. A detection limit of 10 nM was reported. Meanwhile, with this 
method, PDGF-BB in the blood serum of lymphoma patients can be detected directly with good 
stability and selectivity. While attaching aptamers to UCNPs is still in its early stage of development, 
the unique physical properties of these particles are likely to make a major impact in biomedical 
diagnosis. The current sensor designs are mostly for proof-of-concept, and more work is needed to 
establish the long-term stability of their DNA conjugates.  
4.4 Magnetic resonance imaging. Magnetic resonance imaging (MRI) is one of the most powerful 
non-invasive imaging modalities for disease diagnosis, providing three-dimensional examination of 
biological events in living organisms. MRI is based on the relaxation property of protons in an external 
magnetic field, providing contrast in different tissues. Sensing based on MRI is of particular interest 
because it can be easily realized under in vivo conditions. To enhance the quality of MRI, many 
contrast agents have been developed. Among these, superparamagnetic iron oxide nanoparticles 
(SPION) are very attractive due to high biocompatibility and efficiency in dephasing the spins of water 
protons. Lu and co-workers developed a strategy for adenosine detection in human serum using MRI. 
In their report, SPION functionalized with either 3′ or 5′ thiol-modified DNA were assembled with a 
linker DNA. In the absence of adenosine, the nanoparticles were clustered by the linker, while after 
addition of the target, the particles disassembled to give a higher T2 value. By monitoring the T2 
relaxation time of samples with different adenosine concentrations, quantitative analysis was achieved. 
The biosensor retains its activity in human serum (10%) with high selectivity.106 Similar strategies have 
also been applied for detecting thrombin in human serum.119 Hwang et al reported conjugation of a 
nucleolin-targeting aptamer (named AS1411) to cobalt–ferrite NPs with a silica shell, where in vivo 
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imaging of cancer tissues was demonstrated.120 Aptamer-assisted MRI has also been reported with 
other magnetic nanoparticles or aptamers.121,122 
In another approach, a DNA aptamer-conjugated Gd3+ complex was developed. Gadolinium 
compounds are widely used as MRI contrast agents, but they often lack specificity for metabolites. In 
this report, the sensing system consists of an adenosine aptamer attached to a streptavidin, and a 
DOTA-Gd-containing DNA strand that hybridized to a fragment of the aptamer. The rotational 
correlation time of the gadolinium compound is long for the hybridized complex due to its high 
molecular weight. In the presence of adenosine, the Gd-bearing strand dissociates, decreasing the 
molecular weight of the Gd complex and increasing relaxivity. The detection was also demonstrated in 
10% human serum.123 Compared to SPION-based MRI contrast agents, gadolinium-based agents are 
smaller in size and easier for intracellular imaging. A limitation of current MRI contrast agents is that 
high concentrations are required, and aptamer attachment might help solve this issue by increase 
specificity. More in vivo work is needed to further demonstrate its potential. 
4.5. Nanoflare technology. While the previously reviewed examples detect extracellular targets, 
intracellular detection is also desirable. However, there are a few extra difficulties. First, cells do not 
directly internalize nucleic acid probes. In addition, DNA probes are prone to nuclease degradation. 
Finally, measurement of fluorescence in cells often requires a microscope or flow cytometer. Despite 
these difficulties, one such technology called ‘nano-flares’, has been commercialized to detect 
mRNA.124,125 Nano-flares refer to a special fluorescent DNA-AuNP conjugate as shown in Figure 3C, 
except that the quencher is replaced by AuNPs. Compared to molecular dark quenchers (such as 
Dabcyl), AuNPs have better quenching efficiency and longer quenching range.126,127 In the presence of 
target mRNA, the fluorescent DNA probe (flare) is displaced to generate signal. The success of nano-
flare takes advantage of the unique properties of DNA-AuNPs such as enhanced target binding affinity, 
the ability to enter cells, resistance to enzymatic degradation and enhanced colloidal stability.128 In a 
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follow-up work, Mirkin and coworkers developed an aptamer nano-flare probe for directly quantifying 
ATP in living cells.129 In this system, a AuNP core is decorated with a dense layer of chemisorbed ATP 
aptamer. A fluorophore-labeled DNA reporter is hybridized to the aptamer. Upon ATP binding, the 
DNA reporter is dissociated, resulting in fluorescence increase. This nano-flare sensor is sensitive to 
physiologically relevant changes in ATP concentrations (0.1-3 mM) with high selectivity. 
The AuNP platform can also be engineered to detect multiple analytes based on different 
fluorescent probes.130 In a recent report, a multiplexed nanoflare was constructed to detect two distinct 
mRNA targets inside living cells. In addition, this design may also take into account the influence of 
cell-to-cell variation, such as differences in NP uptake. For example, one probe can be used for 
monitoring the target and the other may serve as an internal control for standardization.131 Following 
these results, a sensor for simultaneous detection of three tumor-related mRNA in live cells was 
reported.132  
4.6 Flow cytometry. Flow cytometry employs fluorescence and light scattering for analyzing 
individual cells and particles in a capillary; it is often used for blood analysis in hospitals. With the 
small capillary, the path length of light is significantly reduced and interference from the sample matrix 
might also decrease. Compared to other methods such as dialysis, electrophoresis, centrifugation, 
immobilization, and chromatography, flow cytometry is an excellent approach for separating 
fluorescence detection from the serum sample matrix as it achieves separation without actually 
performing an additional separation step. A few examples have been reported for aptamer-based cell,133 
and small-molecule detection.134 Huang et al combined flow cytometry with aptamer-functionalized 
magnetic microparticles (MMPs) for detecting adenosine in serum using the structure switching 
aptamer design: a quencher labeled DNA is released in the presence of adenosine, leading to 
fluorescence increase.134 The flow cytometer serves to isolate the MMP sensors from the serum and 
detects the fluorescent signal. In particular, the sample volume for adenosine detection can be as low as 
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10 µL, which is desirable for practical applications. The detection limit of adenosine in 90% serum is 
0.2 mM.  
 Since flow cytometers are designed for cell analysis, aptamer binding to cell surface proteins 
has been extensively studied using flow cytometry.135,136 In these studies, aptamers are tagged with a 
fluorophore and target cells can be separated even in a complex sample matrix. For example, Tan and 
co-workers labeled both fluorescent and magnetic NPs with an aptamer targeting a leukemia cell. The 
cells can be enriched using the magnetic NPs from whole blood samples and then detected based on the 
fluorescence using flow cytometry.136 Flow cytometry is currently used in many hospitals for blood 
sample analysis. Therefore, this appears to be a viable platform for developing aptamer-based diagnosis. 
To make it available at a lower cost and for smaller sample volume, microfluidic devices are likely to 
be incorporated as a future direction.137  
4.7 Electrochemistry sensors. The biosensor field is growing on the success story of glucose meters, 
which detect blood glucose using electrochemistry detection. Clearly, the sample matrix effect has been 
nicely resolved using this platform. DNA-based electrochemical detection in complex sample matrices 
such as blood serum,105 crude cellular extracts,138 and soil extracts139 has already been demonstrated. 
Compared to the numerous optical interfering species, the number of electrochemically active species 
in the potential range of most employed redox labels is quite small.140 Electrochemical detection can be 
readily miniaturized and automated with high detection speed, low cost and minimal sample 
consumption. This platform does not require a light source, high-voltage power supplies or other 
sophisticated equipment. Given these advantages, electrochemistry sensors appear well suited for 
practical applications.  
A large number of papers and reviews have been published regarding in this field.19,26,141 We only 
review a few examples here. Xiao et al developed a sensitive, selective and reusable ‘signal-off’ 
electrochemical aptamer-based sensor for thrombin (Figure 5A).142 The sensor is constructed by 
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covalently immobilizing a methylene blue (MB) label on the thrombin-binding aptamer to a gold 
electrode through a thiol group. Since the aptamer chain is initially flexible in the absence of thrombin, 
the MB label is close to the electrode surface to achieve high electron-transfer efficiency. Upon target 
binding, the aptamer folds into its inherent binding structure, inhibiting electron transfer. The sensor 
detects down to 6.4 nM thrombin.  
The signal-off property is undesirable since it is more susceptible to background variation and the 
room for signal change is also small. A ‘signal-on’ approach for direct platelet-derived growth factor 
(PDGF) detection in blood serum was reported (Figure 5B).86 A MB molecule was labeled at the 3-end 
of the PDGF aptamer, and a thiol group was modified at its 5-end to attach to the gold electrode. In the 
absence of the target, the MB label is relatively far away from the electrode surface. PDGF binding 
induces a conformational change and the aptamer forms a stable three-way junction holding the MB 
label close to the electrode, enhancing electron transfer. This method could detect up to 10 nM PDGF 
with a detection limit of 50 pM.  
Further developments in this field include the use of microfluidic sensor chips to achieve 
continuous, real-time and high throughput automated detection.140 Rowe and co-workers developed a 
reusable aptamer-based electrochemical array platform to quickly detect (<10 s) aminoglycoside 
antibiotics in blood samples in order to prevent overdosage or side-effects.143 Ultrafiltration was used 
to remove nuclease to increase the RNA stability. While this pre-treatment step slows the overall 
workflow of the sensor, the sensor detects aminoglycoside at clinically relevant concentrations (2-6 µM) 
in less than 30 min and requires only an inexpensive, desktop centrifuge. With the demonstrated 
examples, electrochemical detection is likely to be a viable means for biomedical diagnosis. An 
interesting recent development is the use of personal glucose meters to work with aptamer-based 
reagents.144,145  
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Figure 5. Electrochemical sensors involving aptamers. (A) ‘Signal-off’ electrochemical biosensor for 
thrombin detection. (B) ‘Signal-on’ electrochemical biosensor for PDGF detection. The aptamer probes 
are immobilized on gold electrode surface via the thiol labels. 
 
4.8 Lateral flow devices. Pregnancy test strips are another success story of biosensors, which are based 
on the lateral flow technology. Lateral flow technology is a popular platform because of its low 
development cost and ease of use. While this platform has been developed to detect numerous targets 
using antibodies, aptamers have been recently tested as well. Using aptamer-linked AuNPs, Lu and co-
worker developed a simple device composed of four overlapping pads placed on a backing: a wicking 
pad, a glass fiber conjugation pad, a membrane, and an absorption pad (Figure 6A).146 The aptamer-
linked and biotin-labeled AuNP aggregates were spotted on the conjugation pad, and streptavidin was 
immobilized on the membrane as a thin line to capture biotinylated AuNPs. When the wicking pad of 
the device is dipped into a solution containing adenosine, the AuNPs are disassembled and migrate 
along the membrane to be captured, forming a red line. Otherwise, the aggregated AuNPs are too large 
to move. Similarly, a cocaine sensitive device was prepared and it performed well in human blood 
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serum.  
 
Figure 6. (A) Aptamer/AuNP-based lateral flow device. Left: adenosine-induced disassembly of 
AuNPs. Biotin is denoted as a black star. Right: schematics of lateral flow devices loaded with 
assembled nanoparticles (on the conjugation pad) and streptavidin (on the membrane) before use (left 
strip), in a negative (middle strip), or a positive (right strip) test. Without adenosine, the aggregated 
AuNPs cannot migrate on the membrane (Reproduced with permission from reference.146 Copyright 
2006, Wiley-VCH) (B) Design principle of lateral flow sensor for thrombin detection. (Reproduced 
with permission from reference.147 Copyright 2009, American Chemical Society.) 
 
Xu and co-workers designed a dry-reagent lateral flow biosensor for visual detection of thrombin 
within 10 min using aptamer-functionalized AuNPs (Figure 6B).147 When dipped into a solution 
containing thrombin, thrombin will move along the device and bind to aptamer-functionalized AuNPs. 
This complex can continue to migrate along the strip and be captured by the secondary aptamer 
immobilized on the test zone (note that thrombin has two aptamer binding sites). AuNPs passing the 
first capture line are then captured by the immobilized cDNA, forming a control line. The dynamic 
range of thrombin was 5-100 nM, and detection limit was 2.5 nM. This study also compared with 
antibody-based strips, where the aptamer strips exhibited similar sensitivity and are even better 
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specificity. The sensor was also capable of detection in human plasma samples. A few other assay 
formats involving bioactive paper and related flow technology have also been reported.148-150 Due to its 
simplicity (in fabrication and for use), lateral flow technology is one of the most successful platforms 
for developing bioanalytical assays. We speculate that this might be one of the first platforms for 
aptamer-based diagnosis to be commercialized. To achieve this, the long-term stability of DNA 
conjugates and their flow property need to be fully studied and optimized with an important target.  
 
4.9. Other sensing methods. Aside from the strategies reviewed above, a number of other 
spectroscopic techniques also show promise in biomedical diagnosis. For example, colorimetric assays 
are attractive for its simplicity in detection.88,151 Using horseradish peroxidase for signal production and 
amplification is a routine method in immunoassays. Interestingly, G-quadruplex DNA with a hemin 
cofactor also shows peroxidase activity.152 Linking aptamers to such DNA has produced biosensors in 
both homogeneous and immobilized format.153-155 For such optical detection to work in complex 
biological samples, the sensor needs to be immobilized so that extensive washing can be carried out to 
minimize background interference. Surface plasmon resonance (SPR) is a highly sensitive method for 
measuring binding on gold surface.156 In this method, binding causes a change in the refractive index 
near the gold surface, which modulates its resonance angle. SPR has been applied to aptamer-based 
detection for detecting serum proteins such as vascular endothelial growth factor (VEGF) down to 1 
pM.63 In the SPR assay format, the probe needs to be immobilized and the assays are carried out in the 
heterogeneous format with the advantage of achieving washing and signal amplification. The SPR 
technology will have more impact by developing portable instruments to reduce the cost. Other 
methods such as localized surface plasmon resonance (LSPR),157 and surface enhanced Raman 
scattering (SERS) have been coupled with aptamers for sensing.158 Their applications in complex 
samples have yet to be fully developed.  
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5. Summary and future directions. 
In the past two decades, the development of aptamer for analytical chemistry is quite remarkable. 
Aptamers have been shown to be versatile and effective as molecular probes for molecular recognition. 
At the same time, numerous methods have been demonstrated to convert aptamer binding into 
physically detectable signals. In many reports, aptamers detect proteins and small molecules with high 
sensitivity and selectivity, comparable to and sometimes even better than those available for antibody-
based assays.147,159,160 Similar to antibodies, aptamers are also a platform technology, making them 
useful to meet the growing need of detecting emerging target molecules.  
Despite these progresses, clinical applications of aptamer-based biosensors for are still lacking. As 
pointed out in this review, a number of issues need to be solved before aptamers can make clinical 
impacts. Addressing these problems will become a major part of the future direction. 1) One of the 
main bottlenecks is the lack of high quality aptamers for clinically important targets. So far the 
majority of the work is carried out with DNA aptamers. To improve the binding property, it is 
worthwhile to look into RNA aptamers. There are many excellent RNA aptamers obtained through 
SELEX and also many riboswitches that can be potentially harnessed as biosensor components. In 
particular, riboswitches already detect important metabolites in physiologically relevant conditions and 
concentrations. Pioneering work in this regard has already been carried out.82,161-163 The technical 
problems involve the synthesis of longer RNA (more than 50 bases). RNA aptamers are often obtained 
from reverse transcription and it is difficult to label them. Maintaining RNA aptamer stability is also a 
challenge, which might be addressed by entrapping them in various materials.164 Another way to 
improve aptamer affinity is to introduce modified bases, which has already been practiced for many 
years for the purpose of improving RNA stability and binding affinity towards certain chemical 
groups.165 The amount of analytical work is still limited, which might relate to the high cost of probe 
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synthesis and difficulty of labelling. We expect that cell-SELEX, tissue-SELEX and other advances 
will continue to be made to obtain aptamers suitable for real diagnosis conditions. 2) To make real 
impacts, efforts are to be focused on clinically important targets. Glucose detection still dominates the 
current biosensor field. To compete with the more established antibodies and protein enzymes, a few 
successful examples need to be demonstrated for aptamers. There are numerous clinical targets and the 
community may need to shift the focus from the proof-of-concept to real applications. For example, 
human epidermal growth factor receptor 2 (HER2) is regarded as a main prognostic or as a therapy-
predictive marker for breast cancer.110 Patients expressing high levels of the HER2 biomarker can be 
effectively treated with Herceptin. Monitoring HER2 is important because of its association with very 
aggressive types of breast cancer.111 Both RNA aptamers (Kd of 3.5 nM)
113 and DNA aptamers (Kd of 
18.9 nM) have been selected.114 More detailed characterizations are needed before they can be applied 
for biosensor development. 3) Recently, the nano-flare technology has been commercialized and many 
AuNP-conjugated probes can be purchased through Millipore. Although they do not directly detect 
aptamer targets, there are reports of using aptamer/AuNPs for cellular detection. Apparently, the use of 
AuNP is crucial for probe stability and assisting cell penetration. Aside from AuNPs, aptamers have 
been attached to many other types of materials and this could provide certain advantages for 
biomedical diagnosis.58 For example, immobilizing aptamers in hydrogels might also be a good way to 
filter interfering species.166-169 4) We have reviewed a few detection methods that show promise for 
biomedical diagnosis. Keeping the sample matrix in mind, these detection methods need to be refined 
and validated to be clinically useful. 5) Unlike antibodies, DNA is highly negatively charged, making 
non-specific electrostatic interaction easy to take place. Since DNA probes are often immobilized on a 
surface to achieve detection, fundamental work is needed to understand the surface interaction between 
DNA, surface and target proteins in a complex sample matrix.170 Fundamental understanding of 
aptamer-target binding interactions in terms of binding affinity, aptamer secondary structure, and 
Kon/Koff is also crucial, which will lead to improved utilization of aptamers for biosensors. 6) Finally, 
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one strategy to address the sensitivity problem is to perform signal amplification. To achieve this goal, 
a large number of methodologies have already been employed, such as using metallic nanoparticles,67 
quantum dots,171-173 DNA machines,154,174-176 PCR,177 and rolling circle amplification (RCA).178 An 
interesting concept, called binding induced self-assembly, takes advantage of proximity or increased 
local concentration. In these systems, protein binding can be converted to DNA assembly with signal 
amplification.179 This also allows ultrahigh sensitivity.180-182 It is important to couple these methods in a 
practically feasible format for biomedical diagnosis. Addressing these challenges will fuel the growth 
of the aptamer field in the future.  
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